All In Biotech

Free tool

FAERS Monitor: Yorvipath

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216490 or its brand name (Yorvipath, Palopegteriparatide). Reports on generic versions are filed under their own applications.

Reports

462

Serious

163

35% of reports

Hospitalization

109

Death reported

8

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hypocalcaemia85
  • hypercalcaemia51
  • injection site reaction40
  • nausea31
  • blood calcium decreased28
  • headache27
  • dizziness23
  • fatigue22
  • paraesthesia21
  • wrong technique in device usage process19
  • product dose omission issue17
  • vomiting15
  • blood calcium increased14
  • diarrhoea14
  • arthralgia13

Reports by year received

View as table
YearReports
20193
20201
20248
202598
2026352

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,697 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypocalcaemiaSignal85205.4169.417,021
hypercalcaemiaSignal51188.9145.79,311
blood calcium decreasedSignal28113.679.33,009
blood calcium increasedSignal1472.843.4920
injection site reactionSignal4026.519.7958
wrong technique in device usage processSignal1918.511.9298
paraesthesiaSignal216.14.085
product dose omission issueSignal172.61.716
dizzinessSignal232.11.412
headache272.01.412
nausea311.81.310
vomiting151.50.92
arthralgia131.40.81
fatigue221.30.91
diarrhoea141.00.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.